Branchburg, NJ, United States of America

David I Stirling

This inventor holds 43 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Celgene Corporation, Biotheryx, Inc., Anthrogenesis Corporation. Active years: 1990-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David I Stirling. Retrieved from https://idiyas.com/inventor/david-i-stirling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 43 (Patent Applications = 8)

% Patents Active = 76.7

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 3)

Average Co-Inventor Count = 2.9

ph-index = 24

Forward Citations = 2,663(Granted Patents)

Location History:

Fanwood, NJ (US) (1990 - 1994)
Branchburg., NJ (US) (2000)
Somerville, NJ (US) (2002 - 2010)
Branchburg, NJ (US) (1994 - 2012)
Warren, NJ (US) (2009 - 2014)
Basking Ridge, NJ (US) (2014 - 2018)

Company Filing History:

Anthrogenesis Corporation

patents

4. 1 out of 1

Celgene Corporation, Et Al.

patent

5. 1 out of 834,708

Other

patents

Years Active: 1990-2018

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

Immunotherapeutic Aryl Amides

Isoindolines

Stem Cell Differentiation

Cancer Treatment

Substituted Biaryl Alkyl Amides

Phthalimides

Cachexia Treatment

Stereoselective Synthesis

Lactams

Enantiomeric Enrichment

Amides

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10106491 - Substituted biaryl alkyl amides (2018-10-23),

2. 9546131 - Substituted biaryl alkyl amides (2017-01-17),

3. 8889411 - Modulation of stem and progenitor cell differentiation, assays, and uses thereof (2014-11-18),

4. 8822527 - Substituted biaryl alkyl amides (2014-09-02),

5. 8288415 - Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione (2012-10-16),

6. 8158653 - Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline (2012-04-17),

7. 7834033 - Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine (2010-11-16),

8. 7709502 - Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines (2010-05-04),

9. 7629360 - Methods for the treatment of cachexia and graft v. host disease (2009-12-08),

10. 7498171 - Modulation of stem and progenitor cell differentiation, assays, and uses thereof (2009-03-03),

11. 7459466 - Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFα levels (2008-12-02),

12. 7329761 - Substituted imides (2008-02-12),

13. 7119106 - Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline (2006-10-10),

14. 7041680 - (R) and (S) isomers of substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and methods of using the same (2006-05-09),

15. 7005438 - Pharmaceutically active isoindoline derivatives (2006-02-28),

Title: The Innovative Mind of David I Stirling

Introduction: David I Stirling, a brilliant inventor based in Branchburg, NJ (US), is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: David I Stirling holds several patents in various technological domains, showcasing his versatility and creativity in inventing new solutions to complex problems.

Career Highlights: Throughout his illustrious career, David I Stirling has consistently pushed the boundaries of innovation, with his inventions revolutionizing industries such as robotics, artificial intelligence, and renewable energy.

Collaborations: David I Stirling has collaborated with leading research institutions, universities, and tech companies to further develop and commercialize his inventions, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: In conclusion, David I Stirling stands as a testament to the power of human ingenuity and creativity in driving technological progress and shaping the future of innovation.

Profile summary based on public USPTO records.